| Title | Quinacrine Enhances Cisplatin-Induced Cytotoxicity in Four Cancer Cell Lines |
| Authors | Wang, Yixiang Bi, Qingwei Dong, Ling Li, Xiao Ge, Xiyuan Zhang, Xiaoxia Fu, Jia Wu, Dengcheng Li, Shenglin |
| Affiliation | Peking Univ, Res Lab Oral & Maxillofacial Surg, Sch & Hosp Stomatol, Beijing 100081, Peoples R China. Beijing Haidian Hosp, Dept Dent, Beijing, Peoples R China. Peking Univ, Res Lab Oral & Maxillofacial Surg, Sch & Hosp Stomatol, 22 Zhongguancun Nandajie, Beijing 100081, Peoples R China. |
| Keywords | Bax Caspase-3 cIAP-1 Cisplatin Cytotoxicity Quinacrine NF-KAPPA-B CYTOCHROME-C NECK-CANCER IN-VITRO THERAPY P53 INHIBITION MECHANISMS RESISTANCE CARCINOMA |
| Issue Date | 2010 |
| Publisher | chemotherapy |
| Citation | CHEMOTHERAPY.2010,56,(2),127-134. |
| Abstract | Background: Quinacrine has potential as a chemosensitizer when combined with chemotherapy, but its anti-cancer mechanisms remain unclear. The purpose of this study was to explore the capability of quinacrine to enhance the cytotoxic effects of cisplatin and the underlying mechanism involved. Methods: The potential role of quinacrine in enhancing the effects of cisplatin was investigated in Hela, SCC-VII, SACC-83 and C6 cancer cell lines with different pathologies. The inhibitory effects of quinacrine plus cisplatin on these cell lines were detected using a CCK-8 assay for viability and a TUNEL assay for apoptosis. The molecules involved in apoptotic signal translation, including cIAP-1, Bax, p53 and cleaved caspase-3, were detected by Western blot to investigate the underlying mechanism. Results: The CCK8 assay showed that quinacrine markedly enhanced the cytotoxicity of cisplatin in a dose-dependant manner in the 4 cancer cell lines. The TUNEL assay showed that treating the 4 cell lines for 24 h with cisplatin plus quinacrine significantly increased the percentage of apoptotic cells compared to treatment with single-agent treatment or untreated controls. Western blot analysis showed that quinacrine plus cisplatin significantly down-regulated cIAP-1 and up-regulated Bax and cleaved caspase-3 expression in Hela and SCC-VII cells compared with single-agent treatment. Conclusions: Quinacrine has the potential to be used as a chemotherapy adjuvant when combined with cisplatin. Copyright (C) 2010 S. Karger AG, Basel |
| URI | http://hdl.handle.net/20.500.11897/344639 |
| ISSN | 0009-3157 |
| DOI | 10.1159/000313525 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 口腔医院 |
